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The quality of on drug information  is measured using
objectivity, availability,  validity and transparency as cri-
teria. Managing drug information  has become a deci-
sive prerequisite for successful medical therapy. The
need to make reliable information on medicines avail-
able to health care professionals and consumers has be-
come an increasingly important feature of the policy on
medicines in the European Union and its Member
States. National Agency for Medicines wants to meet
this demand in Finland with a new, even by internation-
al standards high-grade service.
On NAM’s revised and improved web pages
(www.nam.fi) opened in April, the contents of SPCs
and PILs  authorised in Finland are accessible to anyone
interested in information on medicines. Corresponding
details of medicinal products with the EU’s centralised
marketing authorisation can be accessed via links from
the web pages (http://www.emea.eu.int/) of the Euro-
pean Agency for the Evaluation of Medicinal Products
(EMEA).
NAM’s service covers initially about half the medici-
nal products with marketing authorisation, i.e. roughly
2,000 products. The new service was preceded by a
challenging project involving the conversion of all the
printed product summaries and package inserts into
electronic data prior to being published. The new ser-
vice of the NAM also includes useful search functions.
This work calls for close co-operation between the phar-
maceutical industry and the National Agency for Medi-
cines. The project has, understandably, prepared the
way for more extensive electronic interaction between
the authority and industry.
The SPC (Summary of Product Characteristics) is the
most important published document with regard to the
authorisation procedure. It summarises all relevant in-
formation on the quality, efficacy and safety of the med-
icinal product. Its subject matter is binding on the phar-
maceutical industry in all dissemination of information
on the medicinal product and in its marketing. Health
care professionals in general, and physicians in particu-
lar, should be able access easily and reliable a current,
approved summary of product characteristics. As the
contents need to be amended and approved almost dai-
ly, updated information is in great demand. The SPCs
contain clinical information on the product’s approved
indications, dosage, contraindications, adverse drug re-
actions and interactions.
The PIL (Patient Information Leaflet) is a written in-
struction for the user of the medicine. It is a collection
of essential information promoting the correct and safe
use of the medicine. It is common knowledge that PILs
are easily lost, and it is hard to find necessary informa-
tion on a specific medicine later on. Now anyone who
needs or is interested in such data can make use of the
service where the correct information can be found. It
will be equally easy for physicians to check, what infor-
mation about the prescribed medicine the patient will
get anyway.
The contents of both the summary of product char-
acteristics and the patient information leaflet will con-
form to the marketing authorisation decision or amend-
ment. Summaries of product characteristics are stored in
the database in a manner that enables multiple search
functions in the Internet. Patient information leaflets are
published as they come, in authentic-looking .pdf files,
and may therefore vary in quality and readability.
NAM’s objective is to publish information on all
medicinal products on the market as soon as possible,
and to ensure that the information published already
can be updated fast and flexibly. For that to succeed, it
is naturally important that the pharmaceutical industry
supports this project by going over to using documents
drawn up according to our instructions in electronic da-
ta form. I believe that the pharmaceutical industry is
quite willing to co-operate in this matter. As the service
involves products marketed by pharmaceutical compa-
nies, the publication of correct, error-free product infor-
mation parallel to their competitors’ products on the
web pages of the National Agency for Medicines should
be in the interests of all companies concerned.
The new, challenging service has already been a
learning process in itself, as far as information technolo-
gy and content production, ‘substance’, are concerned.
National Agency for Medicines invites anyone making
use of the new service to give constructive feedback and
new ideas for the further improvement of our drug in-
formation services. 
Translation Liisa Fellman-Paul
Hannes Wahlroos
DIRECTOR GENERAL
National Agency for Medicines
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A unique situation is created by
drug use during pregnancy: the
mother’s illness has to be treated
while the foetus ought not to be
harmed by the drug(s) used in treat-
ment. A good basic rule is to try to
select a drug about which there are
reports concerning experience of the
use during pregnancy, and to try to
avoid the combined use of several
drugs. The smallest possible drug
dose adequate for the mother from
the point of view of treatment
should be used, and, if possible, at-
tempts should be made to divide the
dose into several daily doses to
avoid peak toxic concentrations.
Pregnancy
Since the foetal defects caused by
thalidomide were reported the ef-
fects of drugs on pregnancy and the
foetus have been widely studied.
Nevertheless, the legitimate use of
drugs during pregnancy is still asso-
ciated with many problems. For
many drugs, however, the informa-
tion relating to humans is still too
insignificant to enable the foetal
risks to be assessed reliably. Further-
more, new drugs are continually be-
ing introduced on to the market,
and the classification of the safety of
their use during pregnancy is based
solely on animal studies.
A normal pregnancy without
specific factors of exposure is associ-
ated with a 3% risk of finding some
defects in the newborn. However,
only a couple of percent of all devel-
opmental disorders are thought to
be associated with legitimate drug
use. Nearly all drugs pass the pla-
cental barrier and so are delivered to
the foetus. In addition to causing de-
fects, the adverse drug effect may be
manifested as miscarriage, growth
retardation, foetal death or prob-
lems later in life (e.g. learning diffi-
culties, increased risk of cancer).
Drugs known to cause possible
foetal defects in humans are listed in
Table 1.
Lactation
Nearly all drugs are secreted in the
milk. The concentration in the milk
usually remains very small, however,
and the drug dose received by the
infant through the milk is clinically
insignificant. There are exceptions,
however. Table 2 includes drugs
which are known or suspected to
cause problems when used during
lactation. By no means all drugs
have been studied specifically to find
out how they are secreted in the
milk. The planning of medication
during lactation should follow the
same general principles as those ap-
plied during pregnancy. Drugs which
are only slightly bound to plasma
proteins are also secreted in the
milk. Regular exposure may allow
drugs with a long half-life (or active
metabolites) to accumulate in the
child's body. Premature newborns
with undeveloped drug metabolism
and reduced rate of elimination
form a special group. In many cases
it may be necessary to arrange mon-
itoring of the child. 
Further information on harmful
effects of drugs during pregnancy
and lactation can be obtained from
the teratological information centre
attached to the Family Federation of
Finland. Telephone enquiries (09)
641 716 are received on weekdays
at 9–11 a.m.
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Table 2.   Examples of  drugs with problems during lactat ion.
Should not  be used Not recommended Care should be exercised
Radioactive agents Lithium Drugs with CNS effect
Cytotoxic drugs/cytostatics Immunosuppressive agents New antiepileptics and ethosuximide
Dopamine-agonists (e.g. ciclosporin, azathioprine) Antithyroids
(prevention of secretion of milk) Barbiturates Fluoroquinolone microbials
Narcotics Benzodiazepine with long-term effect Tetracyclines
Synthetic derivatives of vitamin A Chloramphenicol (systemic therapy)
Amiodarone (iodine) New drugs
Gold
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Table 1.   Medicinal substances with explicit  harmful effect on the foetus
MEDICINAL SUBSTANCE ADVERSE FOETAL EFFECT NOTE
Drugs affecting the renin-angiotensin Developmental disorders of the renal Risk associated with use during the 
system (ACE inhibitors, angiotensin II tubules, oligohydramnios and permanent 2nd and 3rd trimester.
antagonists) renal damage and foetal deaths have been Medication should be changed on 
reported. Developmental disorders diagnosis of pregnancy at the latest.
of the bones of the skull. 
Vitamin A derivatives (anti-acne and Frequency of severe multi-organ Restriction of use, monitoring of use.
psoriasis drugs, isotretinoin and abnormalities (heart, CNS etc.) as Accurate information should be given
acitretin) high as 25% after exposure at the to the patient.  
beginning of pregnancy. Reliable contraceptive measures 
Delayed development. should be used. Drugs remain in the 
body for a long time (acitretin even for 
many years) 
Aminoglycosides Potential ototoxicity. Risk associated with parenteral use.
Androgens Masculinisation of female foetus. Risk involved if use continues beyond 
the 8th week of pregnancy.  
Diethylstilboestrol Increased risk of cancer in offspring No longer in use.
(clear-cell carcinoma of the vagina)
Antiepileptics (valproate,  Increased  risk of abnormalities; Planning of pregnancy. 
phenytoin, carbamazepin) multi-organ  abnormalities (valproate, Untreated epilepsy a greater risk
carbamazepine: 1–2% risk of neural to the foetus than medication. 
tube closure defect ).  Foetal damage possibly due to 
Delayed development. inherited predisposition. Folic acid 
supplements (0.4 mg) recommended 
while planning pregnancy and throug-
hout the first trimester. Structural ultra-
sound, AFP measurement.  
Ethanol CNS injury, growth retardation, Harmful throughout pregnancy.
abnormalities, miscarriages. 
Fluconazole (?) Multi-organ abnormalities (skeletal Possible risk associated with high 
development disorders, fissures, heart doses used in the treatment of
defects)? systemic mycosis. 
Narcotics Prematurity, haemorrhages, infections, Harmful throughout  pregnancy. 
abnormalities, withdrawal symptoms of 
the newborn. 
Lithium Risk of cardiac development disorder, After exposure at the beginning of 
estimated to be 1-2% (risk of severe Ebstein's pregnancy, structural  ultrasound
anomaly < 0.1%) of foetal heart during week 18–20.
Misoprostol (used to treat gastric ulcers, Causes miscarriages, can increase the There is an anti-inflammatory analgesic
also used in medical abortions ) risk of abnormalities (development available on the market containing
disorders of limbs, damage  to cranial misoprostol to prevent gastric symp-
nerve nuclei ). toms. Harmful  throughout  pregnancy.
Cytotoxic drugs/cytostatics Multi-organ abnormalities, miscarriages, Following  termination of medication
growth retardation. a precautionary period  should be ob-
served before initiating pregnancy 
(including paternal exposure). 
Thalidomide Multi-organ abnormalities: partial or full New indications (leprosy, autoimmune
absence of limbs, eye and ear anomalies, diseases, metastatic carcinomas,
renal and urinary tract anomalies.  40% risk secondary symptoms associated
of miscarriage and 25% risk of severe with AIDS). Mainly at trial stage, used 
abnormalities after exposure at the with special indications in the USA.
beginning of pregnancy. Close monitoring of use is necessary.
Tetracyclines Developmental disorder of dental enamel, Risk from the 16th week of 
accumulates in the skeleton. pregnancy onwards.
Anti-inflammatory analgesics Harmful effect on the foetal renal function Harmful during the last trimester; 
and blood circulation system (permanent paracetamol appropriate at all stages 
renal damage reported with the use of of pregnancy. 
nimesulide and indomethacin at the end of 
pregnancy, premature closure of shunt channel.  
Warfarin Bone and cartilage development disorders, Medication should be changed immedi-
foetal haemorrhages. ately on diagnosis of pregnancy.
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A total of 748 reports of suspected
adverse drug reactions were received
by the adverse drug reaction register
of the National Agency for Medi-
cines in 2001. About half of them
were serious. The reports were dis-
tributed fairly evenly among various
drugs; only 13 medicinal substances
received more than 10 reports. The
enclosed table cannot be used for
comparing safety among the differ-
ent substances because there is a
considerable variation in the number
of users of various drugs: there may
be more reports concerning a fre-
quently used drug than concerning
one which is used less frequently,
even though the incidence of an ad-
verse reaction may in fact be similar.
The length of time the drug has been
marketed also affects the reporting
of adverse reactions. Reports of all
adverse reactions are specifically re-
quested where newly introduced
drugs are concerned, and there are
consequently more reports on them
than on many old familiar drugs.
The majority of reports (50) of
adverse reactions last year were as-
sociated with the use of nimesulide,
an anti-inflammatory analgesic.
Nearly 70% of the reports (34) were
associated with liver reactions. Up
until mid-March 2002 the National
Agency for Medicines had received a
total of 109 reports on suspected
adverse reactions associated with the
use of nimesulide. Liver reactions
accounted for 66 of them. The ma-
jority of the reports were of symp-
tom-free elevation of liver enzymes
either alone or together with hyper-
bilirubinaemia; serious liver reaction
was reported in 25 of the cases. Two
of the cases necessitated liver trans-
plant, and one was fatal. Due to the
serious liver reactions, the sale of
the tablets and granules of nime-
sulide has been suspended. The Na-
tional Agency for Medicines is at
present reviewing the situation with
the marketing authorisation holder
(Aventis Pharma).
The use of the recent COX-2 se-
lective anti-inflammatory drugs,
celecoxib and rofecoxib, prompted a
total of 36 reports about suspected
adverse reactions last year (20 with
celecoxib, and 16 with rofecoxib).
More than half the reports on cele-
coxib were principally allergic reac-
tions and skin rashes (10 cases).
Celecoxib is a derivative of sulphon-
amide, and should not be prescribed
for patients with hypersensitivity to
sulphonamides. One patient on cele-
coxib therapy was reported as hav-
ing elevated hepatic enzymes. The
adverse reactions reported for rofe-
coxib were fairly evenly distributed
among the various organ systems.
Among these reactions can be men-
tioned the case of an elderly patient
(a 79-year-old woman) who died as
a result of perforated duodenal ul-
cer. The patient was concurrently us-
ing several other drugs, one of
which was acetylsalisylic acid in
small dosage (100 mg/day). Skin
rash or pruritus was reported in on-
ly two patients who received treat-
ment with rofecoxib. Rofecoxib was
introduced on to the market in Fin-
land at the end of 1999 and celecox-
ib in May 2000.
Leflunomide is indicated for use
in adult active rheumatoid arthritis
and introduced into Finland at the
end of 1999. Last year the number
of adverse reactions reported as as-
sociated with its use was 18, seven
of which were related to elevated
hepatic enzymes. Leflunomide may
also cause serious liver reactions,
and consequently, S-ALAT should be
monitored prior to the commence-
ment of leflunomide and at least
once monthly during the first six
months of therapy, and at intervals
of 8 weeks thereafter. If the liver en-
zyme values are rising the dose
should be reduced or the therapy
discontinued (see SPC). Due to the
increased risk of liver reactions con-
current treatment with methotrexate
and/or other hepatotoxic medicinal
substances is not recommended. 
Infliximab is a monoclonal anti-
body which inhibits the biological
activity of tumour necrosis factor al-
pha (TNF-α). It is indicated in se-
vere active rheumatoid arthritis or
Crohn’s disease when the response
achieved with other drugs has been
inadequate. The drug was intro-
duced on to Finnish market in Sep-
tember 1999. Last year 16 reports
on adverse reactions associated with
its use were received, five of which
were related to an allergic reaction.
Three patients were reported as hav-
ing tuberculosis and one had a cy-
tomegalovirus infection. Infliximab
is known to increase susceptibility to
infection and is consequently con-
traindicated in patients with tuber-
culosis or other severe infection. Pa-
tients should in addition be carefully
monitored prior to, during and for
six months following infliximab
therapy in order to exclude tubercu-
Reports received by the ADR register in 2001
Marja-Leena Nurminen
SENIOR MEDICAL OFFICER
Leena Sommarberg
RESEARCHER
National Agency for Medicines
The following medicinal substances
were those most frequently reported to
the ADR register of NAM in 2001. 
Substance Number of 
reports
nimesulide (Nimed) 50
clozapine (Leponex, Froidir) 26
atorvastatin (Lipitor) 20
celecoxib (Celebra) 20
leflunomide (Arava) 18
mirtazapine (Remeron) 17
levofloxacin (Tavanic) 16
infliximab (Remicade) 16
rofecoxib (Vioxx) 16
iopromide (Ultravist) 14
terbinafine (Lamisil) 13
carbamazepine (several preparations,
e.g. Tegretol, Neurotol) 12
esomeprazole (Nexium) 11
Summary 
losis and other infections. 
The majority of reports on
psychotherapeutic drugs concerned
clozapine, a second generation an-
tipsychotic. As in previous years, the
great majority of reports (73%)
were related to cases of granulocy-
topenia or agranulocytosis, one of
which was fatal. An alteration in the
white blood cell count occurs in
about one percent of patients on
clozapine therapy, and a leukocyte
count should consequently be car-
ried out prior to commencement of
therapy and regularly during the
medication. Cardiomyopathy was
reported in one patient on clozapine
therapy. Myocarditis, pericarditis
and cardiomyopathy have been re-
ported as very rare adverse reactions
associated with clozapine therapy.
The possibility of these reactions
should be considered in patients
who develop persistent tachycardia
which continues at rest and is asso-
ciated with arrhythmias, dyspnea
and symptoms of cardiac failure.
The second largest group of re-
ports received on psychotherapeutic
drugs were those associated with
mirtazapine, an antidepressant (17
cases). Six patients were reported as
having CNS symptoms such as hy-
perkinesis, anxiety, hallucinations,
dizziness and headache. Convulsions
were also reported in one patient.
Skin symptoms occasioned the re-
porting in four of the cases and
granulocytopenia/agranulocytosis in
two. Mirtazapine has been in use in
Finland since 1996. Reduction in the
white blood cell count has been re-
ported in previous years in seven pa-
tients in all. Due to potential bone
marrow suppression a warning is in-
cluded in the SPC that mirtazapine
therapy should be discontinued and
a blood count ought to be control if
the patient should develop fever or
sore throat or exhibit other symp-
toms indicative of infection. Mir-
tazapine is a mianserin derivative.
Granulocytopenia and agranulocyto-
sis are adverse reactions known also
to be associated with the use of mi-
anserin.  In the case of both sub-
stances these reactions usually occur
following 4–6 weeks’ use of the
therapy and they usually disappear
on its discontinuation. 
Among statins, the majority of
the reports to the ADR register last
year were related to atorvastatin (20
cases). The second largest number of
reports were related to simvastatin
(9 cases). Liver reaction was the
most typically reported adverse reac-
tion in the use of atorvastatin; seven
patients were reported as exhibiting
elevated liver enzymes, and one pa-
tient had hepatitis. Myopathy was
reported in two patients. Rhabdo-
myolysis was reported in four pa-
tients on simvastatin therapy. Two
of the patients were concurrently re-
ceiving either gemfibrozil or ci-
closporin, which are known to in-
crease the risk of myopathy if used
concurrently with statins. Myopathy
and/or elevated creatinine phospho-
kinase were also reported in two pa-
tients on simvastatin therapy. The
use of statins has increased signifi-
cantly during recent years in Fin-
land. Both atorvastatin and simvas-
tatin are at present among the three
most frequently used statins, which
is probably also reflected in the
number of reports received by the
ADR register.
Among the antibacterials the ma-
jority of ADR reports received con-
cerned levofloxacin of the fluoro-
quinolone group (16 cases), which
has been on sale in Finland since
mid-1998. Most of the reports (9)
referred to adverse reactions on the
Achilles tendon (tendinitis or tendon
rupture). Nearly all the patients
were elderly (over 65 years) and
over half of them were on concur-
rent systemic corticosteroid therapy.
Injury to the tendon can be seen
within two days of the start of med-
ication and it may be bilateral (af-
fecting the tendons of both ankles).
These rare adverse reactions on the
tendon can be considered as a class
effect of all fluoroquinolones. As
with other fluoroquinolones, levo-
floxacin is contraindicated in pa-
tients with previous adverse reac-
tions on the tendon associated with
the use of fluoroquinolones. Elderly
patients are especially at risk. Con-
current corticosteroid therapy in-
creases the risk of tendon rupture. If
tendinitis is suspected, the adminis-
tration of fluoroquinolones should
be discontinued immediately.
The majority of adverse reactions
reported on antifungals were associ-
ated with the use of terbinafine
tablets (13 cases). Six of the ADR
reports concerned various skin reac-
tions; one of the reports described a
bullous rash similar to that mani-
fested in toxic epidermal necrolysis,
i.e. Lyell’s syndrome. This serious
skin reaction is included as a very
rare adverse reaction in the SPC of
terbinafine. Liver reactions associat-
ed with terbinafine therapy were al-
so reported (2 reports of elevated
liver enzymes, 1 of hepatitis).
Iopromide is a low-osmolar, io-
dine-containing contrast medium
used in angiography, urography and
contrast-enhanced computerised to-
mography. In 2001, the NAM re-
ceived a total of 14 reports on ad-
verse reactions caused by it, the ma-
jority of which were allergic reac-
tions (urticaria, anaphylaxis). Spe-
cial care must be exercised in the use
of this preparation in patients who
are hypersensitive to iodine. Hyper-
sensitivity occurs most often in pa-
tients susceptible to allergies. Pre-
vention of hypersensitivity reactions
may be tried; for instance, by giving
the patient antihistamines and/or
corticosteroids before the examina-
tion.
The majority of reports about
antiepileptics were associated with
carbamazepine (12 cases). The ad-
verse reactions were typical of those
occurring during carbamazepine
therapy, mostly related to elevated
liver enzymes (4) and changes in the
blood cells (4). One of the patients,
a 47-year-old woman practically
confined to bed at an institution for
mentally retarded patients since
birth, died of liver damage suspected
to have been caused primarily by
phenytoin and secondarily by carba-
mazepine. The patient had also been
receiving several other drugs.
The majority of ADR reports
last year concerning drugs intended
for gastrointestinal diseases were as-
sociated with the use of a new pro-
ton pump inhibitor, esomeprazole
(11 cases). Six of these reports were
about various skin reactions or aller-
gic reactions. One patient (a 72-
year-old man) was reported as hav-
ing had a fatal myocardial infarc-
tion, but the causal effect of the
drug was considered unlikely. Es-
omeprazole is an S-isomer of ome-
prazole. The drug was introduced
on to the Finnish market in January
2001.
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Despite the quality assurance mea-
sures a drug may be released on for
consumption, which does not fulfil
the quality criteria required or
which is supplied with package la-
belling not complying  with the mar-
keting authorisation or with the type
of labelling which is required, and
we are dealing with a product de-
fect.  The marketing authorisation
holder is responsible for managing
any product defects.  Handling de-
fects occurring in drugs manufac-
tured at pharmacies, hospital phar-
macies, medicine centres, is the re-
sponsibility of the person in charge
of the respective unit of manufactur-
ing.  According to the regulation of
the National Agency for Medicines
on product defects (1/1999) all
pharmaceutical entrepreneurs are re-
sponsible, on their part and in ac-
cordance with the Medicines Act,
for the measures required by prod-
uct defects detected and for ensuring
that the measures are appropriate.
To ensure effective and rapid
prevention of any harm to the user
arising  from the product defect, or
to reduce the harm to the minimum,
pharmaceutical entrepreneurs should
be well prepared to handle product
defects.  Such preparedness requires
guidelines for operation and staff
training in respect to any occurrence
of product defects.
The National Agency for Medi-
cines is the supervisory authority 
in Finland controlling appropriate 
handling of product defects. If de-
fects are not appropriately handled
by the parties responsible, the Na-
tional Agency can ban the distribu-
tion, sale and supply for consump-
tion of a batch of a defective prod-
uct.   Nonetheless, the operations of
the marketing authorisation holders
and drug manufacturers have  been
carried out responsibly, and the Na-
tional Agency has had no need to in-
terfere with product defects by
means of the bans referred to in Sec-
tion 101 of the Medicines Act.  
Assessing the risks arising from
product defects ...
To control that the measures taken
in the management  of product de-
fects are effective and correctly bal-
anced with regard to any danger or
damage faced by the user, a classifi-
cation system based on the severity
of the defect is employed. Based on
risk assessment, the product defects
are classified as dangerous (Class 1),
harmful (Class 2) or minor (Class
3).  Any risk to which the drug user
is exposed  by a product defect
should always be assessed individu-
ally.  Risk assessment requires ex-
pertise.  For instance, the National
Agency for Medicines may in certain
cases request  from the marketing
authorisation holder a statement by
a medical expert with regard to  any
undesirable effects the drug may
have on its user.  The choice of mea-
sures is governed by the product de-
fect classification system.  Neverthe-
less, measures cannot always be tak-
en categorically in respect, for in-
stance, of products of which there
are no batches free from defects and
for which no replacement prepara-
tion exists on the market.  In similar
situations the only alternative is to
compare the risk arising from a
product defect with the problem of
non-availability which would be
caused by a ban on the sale of the
preparation.  Both of these aspects
ought to be considered in choosing
the measures required.  If the risk to
the user caused by the defect is diffi-
cult to assess, a principle of precau-
tion has usually been followed and
any measures taken have focused on
minimising any undesirable effects
caused by the defect.
Information on product defects
Ari Kiskonen
SENIOR PHARMACEUTICAL INSPECTOR
Eeva Leinonen
SENIOR PHARMACEUTICAL INSPECTOR
National Agency for Medicines
Despite all necessary quality assurance measures product defects are still possible, and advance pre-
paredness for their management should be in place. Even though the responsibility for the man-
agement of a product defect lies with the marketing authorisation holder, all pharmaceutical en-
trepreneurs are for their part obliged to take any measures made necessary by a product defect and
to ensure that the measures taken are appropriate. Good operational preparedness for managing
product defects is maintained by plans and guidelines for such management and by regular train-
ing of staff in regard to future situations where product defects may occur.
Summary 
... setting in motion the neces-
sary measures ...
Defective products of Classes 1–3
are removed from sale and distribu-
tion. Defective products which may
be life-threatening and may compro-
mise the health of the user are also
removed from consumption.  To
prevent or restrict the potential un-
desirable effects of a product defect,
measures may have to be set in mo-
tion even if the assessment of unde-
sirable effects caused by the defect
was  incomplete at the time.  The
marketing authorisation holder may,
for instance, impose a ban on the
distribution of the defective product
immediately upon detection of the
defect and decide to prohibit its sale
as soon as possible after the precise
risk assessment is concluded and the
availability of a replacement product
is ensured.  A record should always
be kept of the measures adopted in
managing a product defect.
... and informing the relevant
parties.
It is required by  regulation 1/1999
of the National Agency for Medi-
cines on product defects  that the
parties responsible for the manage-
ment of a product defect inform the
National Agency  promptly follow-
ing  the necessary preliminary re-
views and after any immediate mea-
sures have been taken.  This proce-
dure of notification is only part of
the necessary communication associ-
ated with product defect manage-
ment.  The information should be
disseminated quickly and reliably
among all relevant parties, such as
the pharmaceutical manufacturer re-
leasing the drug for sale and con-
sumption or other pharmaceutical
manufacturer, the wholesaler re-
sponsible for the distribution, the
pharmacy in charge of the supply
for consumption, the hospital phar-
macy or drug centre and the domes-
tic and foreign drug control authori-
ties.  The information should also be
extended to the consumer as neces-
sary.  It is important that both the
communication aimed at the con-
sumers and that among pharmaceu-
tical entrepreneurs and the authori-
ties is open, reliable and correctly
timed and that its contents are clear.
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A significant proportion of the reports
on product defects are received as RAS
(RAPID ALERT SYSTEM) reports from
drug control authorities in other coun-
tries.  The RAS reporting procedure is
based on policies approved by the EU
and on agreements between authorities.
Reports on product defects or suspected
defects are customarily also received
from marketing authorisation holders,
pharmaceutical wholesalers, hospital
pharmacies and retail pharmacies.  
For instance, when one drug was being
checked and prepared for supply in a
pharmacy in 2001, it was noticed that
the name of the drug printed on the in-
ner package was not the same as that on
the outer package.  The mistake was
spotted by the pharmacy staff as they
were attaching the instructions to the in-
ner package.  Had the instructions been
attached incorrectly to the outer card-
board package of the drug and the pack-
age contents left unchecked, the mis-
take would have gone unnoticed.
Translation Mervi Moisander
